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Abstract
Introduction: Clinical conduct can influence the healing of injured tissue. Eradication 
of inflammation seemed a promising strategy to promote musculoskeletal healing until 
studies showed a delayed/incomplete recovery from partial or complete elimination 
of inflammation. Endogenous lipid mediators biosynthesized from omega-3 and some 
from -6 fatty acids are molecules potentially playing important roles in the resolution 
of inflammation. Using such lipid mediators to treat injuries represents an attractive 
approach due to their anti-inflammatory and pro-resolving roles. Our goal was to 





) to stimulate myoblast proliferation. 
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-induced stimulating ef-
fect of L6 cell proliferation (60% and 75%, respectively). 15∆-PGJ
2
was present in 
the intracellular and extracellular compartments under basal conditions, but was not 
modulated by PAR-2 receptor activation.
Conclusion: L6 muscle cell can produce 15∆-PGJ
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and its effect on cell proliferation 






15∆-PGJ2: 15-deoxy-delta-12,14-Prostaglandin J2; α-MEM: 
α-Minimum Essential Medium; BHT: Butylated hydroxytoluene; 
CRTH2:Chemoattractant receptor of Th2 cells; COX-2: 
Cyclooxygenase-2; DP: D Prostanoid; FBS: Fetal bovine serum; 
LC-MS/MS: Liquid chromatography coupled to tandem mass 
spectrometry; NF-κB:Nuclear factor-κB; PPAR: Peroxisome 
proliferator-activated receptor; PG: Prostaglandin; PAR: 
Protease-activated receptor; PUFA: Polyunsaturated fatty acids
INTRODUCTION
The proper management of tissue damage-induced 
inflammation represents an important element in the treatment 
of sport related acute injuries. While many efforts were devoted 
to the development of anti-inflammatory strategies, an abundant 
literature subsequently demonstrated that the inflammatory 
response is essential for regeneration and its partial or complete 
elimination can induce delayed and/or inappropriate healing [1-
6]. Clearly, new treatment strategies to be developed should aim 
at promoting regeneration without targeting the inflammatory 
process.
Formerly regarded as a passive mechanism, the resolution of 
inflammation is now recognized as an active process modulated 
by the endogenous and timely production of pro-resolution 
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and anti-inflammatory molecules [7,8]. Resolvins, protectins 
and marseins are lipid mediators biosynthesized from omega-3 
fatty acids that can potentially play important roles in the anti-
inflammatory and pro-resolving processes [9]. In addition, 
some lipid mediators derived from omega-6 arachidonic acid, 
such as lipoxins and the cyclopentanone 15-deoxy-delta-12,14-
Prostaglandin J2 (15∆-PGJ2), also have anti-inflammatory and 
pro-resolving effects [10].
The metabolite 15∆-PGJ2 is formed by a double spontaneous 
dehydration of prostaglandin (PG) D2 into PGJ2 and PGJ2 into 
15∆-PGJ2 and acts on different targets to accomplish a wide 
array of effects [11]. 15∆-PGJ2 can promote the resolution of 
inflammation by inhibiting the activity of the transcription factor 
nuclear factor-κB (NF-κB) [11]. 15∆-PGJ2 can also bind the PGD2 
receptors: D prostanoid (DP) 1 and 2 receptors (DP2 receptor is 
also designed chemoattractant receptor of Th2 cells (CRTH2)), 
whose activation can lead to various inflammatory and anti-
inflammatory effects such as vasodilatation, suppression of 
cytokine production, activation of immune cells and inhibition of 
platelet aggregation and chemotaxis [11,12]. Moreover, 15∆-PGJ2 
can respectively have mitogenic and differentiation-promoting 
effects in several cell types such as fibroblasts and adipocytes 
following its interaction with one of its natural receptor, the 
peroxisome proliferator-activated receptor (PPAR) y [13,14]. 
We also recently found that 15∆-PGJ2 can also stimulate skeletal 
muscle cell proliferation in vitro [15].
The quest to develop new and innovative therapeutic 
strategies providing faster and more complete recovery from 
musculoskeletal injury is highly relevant in the field of sports 
medicine. The study of newly identified endogenous anti-
inflammatory/pro-resolving mediators becomes attractive. 
Our objective was to provide a better understanding of how the 
metabolite 15∆-PGJ2 can influence myoblast proliferation, a key 
step in muscle healing, by identifying the intracellular and/or 
extracellular targets of 15∆-PGJ2 responsible for the stimulation 
of L6 myoblast proliferation.
MATERIALS AND METHODS
Cell culture and proliferation assays 
L6 rat skeletal myoblasts (ATCC, Manassas, VA, USA) were 
maintained in α-Minimum Essential Medium (α-MEM) (HyClone, 
Logan, UT, USA) supplemented with 10% fetal bovine serum 
(FBS) (HyClone, Logan, UT, USA) at 37 oC, 5% CO2.
For measurements of proliferation rate, cells were seeded 
onto 96-well plate at a density of 3,000 cells/well in 65 mL of 
α-MEM containing 1% FBS. The number of viable cells after 
24 h of incubation was determined by the use of Cell Titer 96® 
Aqueous One Solution cell proliferation assay (Promega, Madison, 
WI, USA) according the manufacturer’s instructions. Various 
receptors known as potential targets for 15∆-PGJ2 were tested: 
BW 245C (5 nM, 0.01 µM, 2 µM, 5 µM), a selective agonist of DP1 
receptor (Cayman Chemical, Ann Arbor, MI, USA), indomethacin 
(50 nM, 500 nM, 5000 nM) (Sigma-Aldrich, St. Louis, MO, USA) a 
DP2 agonist, GW 0742 (1 nM, 50 nM, 100 nM, 1 µM) a selective 
PPARδ agonist (Cayman Chemical, Ann Arbor, MI, USA) [16-
18]. Since 15∆-PGJ2 or trypsin can increase L6 cell proliferation 
[15], these compounds were used as positive control and to 
evaluate the effect of the DP1 and DP2 antagonists (BW A868C 
and BAY-u3405 (Ramatroban), respectively) on L6 myoblast 
proliferation by pre-incubating myoblasts with the antagonists 
for 30 min at 37°C before the addition of 15∆-PGJ2 or trypsin. 
DP1 and DP2 antagonists were purchased from Cayman Chemical 
(Ann Arbor, MI, USA). 
Western blots of DP1 and DP2 receptors in L6 cells
L6 myoblasts were lysed and protein content was assessed 
according to Duchesne et al. (2013) [19]. DP1 and DP2 were 
immunoprecipitated with Protein A Sepharose 6MB beads (GE 
Healthcare, Cat # 17-0469-01). To do so, samples were first pre-
incubated with goat serum (Sigma-Aldrich, St-Louis, MO, USA). 
After Protein A Sepharose 6MB beads were washed in lysis 
buffer, primary antibodies DP1 (Santa Cruz, Cat. # sc-55815) and 
DP2 (Santa Cruz, Cat. # sc-23092) were incubated with samples 
overnight at 4 oC. Beads were then added to each sample and 
incubated overnight at 4oC. Samples were centrifuged and the 
supernatant thrown out. Pellets were suspended in western 
sample loading buffer (65 mM Tris-base pH 6.8, 26.2% glycerol, 
2.1% SDS, 0.52% 2-mercaptoethanol (Sigma-Aldrich, St-Louis, 
MO, USA) and a few grains of bromophenol blue (Bio-Rad, 
Hercules, CA, USA). Samples were boiled to release the antibody 
from the beads and the supernatants were kept for western blots 
analysis.
Western blots were performed according to Duchesne et al. 
(2013) [19]. After transfer, membranes were incubated at RT for 
2 h with DP1 and DP2 antibodies (dilution 1/200). The secondary 
antibody used was a donkey anti-goat IgG-HRP-conjugated 
(Santa Cruz, Cat. # sc-2020; dilution 1/10,000).
Measurement of 15∆-PGJ2 concentration
15∆-PGJ2 concentration was measured by liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/
MS). L6 cell culture medium was replaced by α-MEM without FBS 
but containing 0.005% butylated hydroxytoluene (BHT) (Sigma-
Aldrich, St. Louis, MO, USA) as an antioxidant [20]. Cells were 
stimulated or not with 200 nM trypsin for 3h (Sigma-Aldrich, St. 
Louis, MO, USA). Culture medium was then removed and cells 
were detached. A solution deuterated-15∆-PGJ2 (15∆-PGJ2-D4; 
Cayman Chemical, Ann Arbor, MI, USA) was added to culture 
medium as an internal standard before extraction steps. After 
acidification of the samples, extraction steps were performed 
according to Yang et al. (2002) [21]. Analyses were performed 
in the laboratory of the Bioanalytical Services of the Centre 
Hospitalier Universitaire de Québec (CHU de Québec), Laval 
University, Qc, Canada (http://services.crchuq.ulaval.ca/groups/
bioanalytique/wiki/c00fb/Welcome.html) according to Yang 
et al. (2002) using a API4000 mass spectrometer (AB Sciex, 
Concord, On, Canada) [21].
Statistical analysis
All values are expressed as means and standard error. 
Comparisons between groups were performed by Student’s 
t-test or one-way ANOVA followed by Tukey-Kramer post-hoc 
test, when appropriate (InStat GraphPad Software Inc., La Jolla, 
CA, USA). Significance was defined as p < 0.05.
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RESULTS AND DISCUSSION
Inflammation has been traditionally considered as harmful 
and many anti-inflammatory strategies were thus developed 
to eradicate inflammation in the context of musculoskeletal 
injuries. However, it has been subsequently demonstrated 
that elimination of inflammatory actors often leads to delayed 
tissue healing [2,22,23]. An abundant literature has recently 
emerged concerning the anti-inflammatory and pro-resolution 
effects of some omega-6 and omega-3 fatty acids-derived lipid 
mediators [7-12]. While it is clearly documented that excessive 
amounts of omega-6 polyunsaturated fatty acids (PUFA) leading 
to a high omega-6/omega-3 ratio promote the pathogenesis 
of cardiovascular disease, cancer and inflammatory and 
autoimmune diseases [24,25], surprisingly some lipids derived 
from arachidonic acid possess anti-inflammatory properties. 
Indeed, Gilroy et al. (1999) reported for the first time that 
cyclooxygenase-2 (COX-2) was not only an inflammatory actor, 
but can also allow the formation of the anti-inflammatory 
cyclopentanone 15∆-PGJ2 [10]. This lipid mediator can accelerate 
resolution of inflammation by diverse mechanisms such as 
providing signals that selectively stop neutrophil infiltration, 
stimulate non-phlogistic recruitment of monocytes, and activate 
macrophage phagocytosis of apoptotic cells, to name a few. On the 
other hand, 15∆-PGJ2 can induce mitogenic and differentiation-
promoting effects in some cell types [13-15]. However, in skeletal 
muscle cell, not much is known on the receptors involved and the 
mechanism of action.
In general, it is assumed that 15∆-PGJ2 can induce its effects 
by interacting with one of its natural receptor, PPARγ [15], but 
this nuclear receptor  is very weakly expressed in skeletal muscle 
[26]. It is also possible that 15∆-PGJ2 binds the extracellular 
PGD2 receptors DP1 and DP2 [11,12], which are typically found 
on bronchial smooth muscle, vascular smooth muscle, dendritic 
cells and platelets for DP1 and on Th2 lymphocytes, eosinophils 
and basophils for DP2 receptor [27]. The first step of this study 
was then to assess the presence of DP1 and DP2 receptors in L6 
skeletal muscle cell. We found that both receptors are present 
in L6 cells (Figure 1). These results may seem contrary to those 
reported by Veliça et al. (2010), but it is important to highlight 
that they evaluated only the mRNA expression of DP1 and DP2 
receptors in a different cell line (C2C12) [28].
This observation prompted us to verify whether these 
extracellular receptors could be implicated in the 15∆-PGJ2-
induced skeletal muscle cell proliferation that we previously 
observed [15]. To do so, L6 myoblasts were incubated with 
different DP agonists to evaluate their impact on skeletal muscle 
cell proliferation. We found that the DP1 agonist BW 245C did not 
modulate L6 cell proliferation at any of the concentrations tested 
(Figure 2A). We next blocked the DP1 receptor using the specific 
antagonist BW A686C to evaluate its implication in 15∆-PGJ2-
induced L6 cell proliferation; we first verified that incubation of 
L6 cells with the antagonist alone (1 µM) did not influence the 
proliferation rate of L6 cells (data not shown). As previously 
reported, L6 cell proliferation was increased by 56 % above 
control when 15Δ-PGJ2 was added to myoblasts for 24 h (Figure 
2A). Interestingly, pre-incubation of L6 cells with DP1 antagonist 
caused a significant inhibition of 60% of the stimulating effect 
of 15∆-PGJ2 on L6 cell proliferation suggesting that DP1 receptor 
is, at least partially, implicated in 15∆-PGJ2-induced mitogenic 
effect (Figure 2C). The absence of effect of the DP1 agonist 
on L6 cell proliferation is likely related to the experimental 
conditions chosen. The 24 h time period selected might have 
been inappropriate to observe the effect of a compound like 
BW 245C, which has a different half-life and stability in culture 
medium compared to 15∆-PGJ2. In addition, functional selectivity 
or biased agonism, a phenomenon by which the activation of the 
same receptor by different agonists lead to different signaling 
response and already identified in prostanoid receptors, 
could also explain such observations [29]. Furthermore, as 
demonstrated by Petrova et al. (1999), the metabolite 15∆-PGJ2 
can be more effective than a specific receptor agonist [30]. 
The culture of L6 cells with indomethacin, an agonist of the 
DP2 receptor, slightly increased the proliferation of L6 myoblasts, 
reaching a significant response of 20 % above control at a 
concentration of 500 nM (Figure 2B). Pre-incubation of L6 cells 
with the DP2 specific antagonist BAY-u3405 decreased by 75% 
the stimulating effect of 15∆-PGJ2 on L6 cell proliferation (Figure 
2C); again, incubation of L6 cells with the antagonist alone did 
not impact on cell proliferation (data not shown). These results 
strongly suggest that DP2 receptor is used by the metabolite 15∆-
PGJ2 to induce its proliferative effect. To the best of our knowledge, 
this study is the first to identify skeletal muscle cell extracellular 
targets used by 15∆-PGJ2 to accomplish its mitogenic effect, a key 
step in skeletal muscle repair. 
As previously mentioned, PPARγ is a target of 15∆-PGJ2 used 
to stimulate proliferation in certain cell types, but this cascade 
is presumably inexistent in skeletal muscle cell in vivo as PPARγ 
is very weakly expressed. Since PPARδ, an ubiquitous member 
of the PPAR family, is present in skeletal muscle cells, as a 
preliminary experiment we tested the possibility that this nuclear 
receptor is involved in the stimulation of L6 cell proliferation by 
15∆-PGJ2. A 24 h incubation of L6 cells with GW 0742, a specific 
PPARδ agonist, significantly stimulates cell proliferation at the 
concentration of 50 nM (Figure 2D). As previously reported 
Figure 1 Expression of DP1 (duplicate) and DP2 receptors in L6 
myoblasts by western blotting.
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Figure 2 L6 myoblast proliferation following treatment with either 
(A) – DP1 agonist BW 245C, (B) – DP2 agonist indomethacin or (D) – 
PPARδ agonist GW 0742, while control wells received medium with 
1% FBS only and positive control wells received 15∆-PGJ2 or trypsin. 
(C) – L6 myoblasts were pre-incubated either with DP1 antagonist BW 
A868C or DP2 antagonist BAY-u3405 before the addition of 15∆-PGJ2. 
*Significantly different from control, P < 0.05.
Figure 3 (A) – Extracellular and (B) – intracellular concentration of 
15∆-PGJ2  following a 3 h incubation of L6 cells with or without trypsin, 
a PAR-2 agonist.
[31], activation of this nuclear receptor can stimulate myoblast 
proliferation and it can be assumed that 15∆-PGJ2 may target this 
intracellular nuclear receptor to induce its proliferative effect. 
However, this field deserves a more complete investigation.
The second objective of the study was to verify if 15∆-PGJ2 
is produced by L6 muscle cells following protease-activated 
receptor (PAR)-2 activation, as seen with fibroblasts in culture. 
15∆-PGJ2 was detected in L6 cell culture media under basal 
conditions after 3 h in culture (Figure 3A). However, this 
extracellular concentration of 15∆-PGJ2 remained statistically 
unchanged when L6 cells were stimulated with trypsin 200 
nM (Figure 3A). These results prompted us to verify if 15∆-
PGJ2 is produced intracellularly by L6 cells following PAR-2 
activation without being thereafter externalized. Culture media 
Central
Côté et al. (2015)
Email: 
Ann Sports Med Res 2(4): 1027 (2015) 5/6
surrounding L6 cells was thus removed at the end of incubation 
period and cells were lysed. A level of 15∆-PGJ2 comparable to 
the one observed in extracellular media was measured in L6 cell 
homogenates (Figure 3B) and trypsin-induced PAR-2 activation 
[15] did not influence the intracellular concentration (Figure 
3B). Overall, the experimental protocol used clearly allowed to 
show that L6 cells can produce 15∆-PGJ2, but we were unable to 
demonstrate that its production was sensitive to PAR-2 receptor 
activation. The complex and costly procedures involved in the 
extraction and measurement of this molecule makes it difficult 
to perform protocols with various time course designs in terms 
of duration of stimulation and sampling post-stimulation. 
Further work is needed before one can conclude solidly on the 
responsiveness of 15∆-PGJ2 production to PAR-2 activation.
Thus, key elements of the signaling cascade leading to skeletal 
muscle cell proliferation following PAR-2 activation remain to 
be discovered. We were able to demonstrate that 1) 15∆-PGJ2 is 
produced by skeletal muscle cell and 2) DP1 and DP2 receptors are 
expressed in skeletal muscle cells. We have thus identified intra- 
and extracellular receptors potentially used by this metabolite 
to induce its proliferative effect. Even if we were unable to 
demonstrate that PAR-2 activation leads to an increased 15∆-
PGJ2 production, our results remain very physiologically relevant 
since 15∆-PGJ2 can also be released by other cell types found in 
skeletal muscle, such as fibroblasts and mast cells, under basal 
and inflammatory conditions [13,32]. The discovery of receptors 
used by the metabolite 15∆-PGJ2 can lead to the development of 
new therapeutic approaches in the treatment of musculoskeletal 
injuries relying on endogenous molecules synthesized during the 
period of resolution of inflammation. Further studies focusing on 
the interaction of 15∆-PGJ2with nonreceptor protein following its 
entry into cells, possibly by an active transport system [11], are 
needed to complete our observations. Indeed, as demonstrated 
by Oliva et al. (2003), the direct activation of Ras/Erk MAP kinase 
pathway by 15∆-PGJ2 at cytosolic level may be a key element in 
the myogenic process [33].
CONCLUSION
The treatment of musculoskeletal injuries takes an enormous 
place in the field of sport medicine and there is obviously room 
to improve clinical conduct which is not always evidence-
based. The fine understanding of the processes leading to tissue 
repair following acute injury is critical for ensuring an optimal 
treatment and healing. This is particularly true for the athlete 
population, where complete recovery of original tissue strength 
must be aimed to avoid re-rupture of structures submitted to high 
mechanical stress. Lipid mediators have been largely studied in 
disease models, but their implication in the treatment of acute 
musculoskeletal injury remains relatively unexplored. It seems 
promising to study the effect of 15∆-PGJ2 on muscle repair since 
in addition to its anti-inflammatory properties, mitogenic effects 
have been associated to this metabolite.
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